新型三唑类药物与已有的抗真菌药物对红色毛癣菌的体外活性比较。
Comparison of the in vitro activities of newer triazoles and established antifungal agents against Trichophyton rubrum.
作者信息
Deng Shuwen, Zhang Chao, Seyedmousavi Seyedmojtaba, Zhu Shuang, Tan Xin, Wen Yiyang, Huang Xin, Lei Wenzhi, Zhou Zhaojing, Fang Wenjie, Shen Shuaishuai, Deng Danqi, Pan Weihua, Liao Wanqing
机构信息
Shanghai Institute of Medical Mycology, Department of Dermatology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Department of Medical Microbiology, Radboudumc, Nijmegen, The Netherlands Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands Invasive Fungi Research Center, Mazandaran University Medical Center, Sari, Iran.
出版信息
Antimicrob Agents Chemother. 2015 Jul;59(7):4312-4. doi: 10.1128/AAC.00244-15. Epub 2015 Apr 20.
Abstract
One hundred eleven clinical Trichophyton rubrum isolates were tested against 7 antifungal agents. The geometric mean MICs of all isolates were, in increasing order: terbinafine, 0.03 mg/liter; voriconazole, 0.05 mg/liter; posaconazole, 0.11 mg/liter; isavuconazole, 0.13 mg/liter; itraconazole, 0.26 mg/liter; griseofulvin, 1.65 mg/liter; and fluconazole, 2.12 mg/liter.
摘要
对111株红色毛癣菌临床分离株进行了7种抗真菌药物的测试。所有分离株的几何平均最低抑菌浓度按升序排列为：特比萘芬0.03毫克/升；伏立康唑0.05毫克/升；泊沙康唑0.11毫克/升；艾沙康唑0.13毫克/升；伊曲康唑0.26毫克/升；灰黄霉素1.65毫克/升；氟康唑2.12毫克/升。
相似文献
1
Comparison of the in vitro activities of newer triazoles and established antifungal agents against Trichophyton rubrum.
Antimicrob Agents Chemother. 2015 Jul;59(7):4312-4. doi: 10.1128/AAC.00244-15. Epub 2015 Apr 20.
2
In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs.
Mycoses. 2015 May;58(5):303-7. doi: 10.1111/myc.12315. Epub 2015 Mar 10.
3
[Evaluation of the in vitro susceptibility pattern of clinical isolates of Trichophyton mentagrophytes and Trichophyton rubrum in Santiago, Chile].
Rev Iberoam Micol. 2015 Apr-Jun;32(2):83-7. doi: 10.1016/j.riam.2013.12.002. Epub 2014 May 2.
4
Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis.
J Mycol Med. 2020 Jun;30(2):100935. doi: 10.1016/j.mycmed.2020.100935. Epub 2020 Jan 30.
5
Antifungal susceptibility testing of Trichophyton rubrum by E-test.
Arch Dermatol Res. 2007 May;299(2):107-9. doi: 10.1007/s00403-006-0731-8. Epub 2007 Feb 28.
6
susceptibility of dermatophytes to oral antifungal drugs and amphotericin B in Uttar Pradesh, India.
Indian J Dermatol Venereol Leprol. 2019 Jul-Aug;85(4):388-392. doi: 10.4103/ijdvl.IJDVL_319_18.
7
Comparison of in vitro activities of newer triazoles and classic antifungal agents against dermatophyte species isolated from Iranian University Hospitals: a multi-central study.
Ann Clin Microbiol Antimicrob. 2023 Feb 20;22(1):15. doi: 10.1186/s12941-023-00564-4.
8
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
Antimicrob Agents Chemother. 2007 May;51(5):1818-21. doi: 10.1128/AAC.01217-06. Epub 2007 Feb 16.
9
In vitro activities of four antifungal drugs against Trichophyton rubrum isolates exhibiting resistance to fluconazole.
Mycoses. 2007 Jul;50(4):286-9. doi: 10.1111/j.1439-0507.2007.01325.x.
10
[In vitro activity of voriconazole and three other antifungal agents against dermatophytes].
Enferm Infecc Microbiol Clin. 2003 Nov;21(9):484-7. doi: 10.1016/s0213-005x(03)72992-9.
引用本文的文献
1
Comparative Analysis of Susceptibility Profile of Dermatophytes Against 8 Antifungal Agents: A Cross-Sectional Study.
Indian J Dermatol. 2025 May-Jun;70(3):117-124. doi: 10.4103/ijd.ijd_647_23. Epub 2025 May 8.
2
Improving treatment of chromoblastomycosis: the potential of COP1T-HA and antimicrobial photodynamic therapy against .
Mycology. 2024 Aug 28;16(1):413-417. doi: 10.1080/21501203.2024.2383640. eCollection 2025.
3
Design, synthesis, docking studies and bioactivity evaluation of 1,2,3-triazole eugenol derivatives.
Future Med Chem. 2024;16(18):1883-1897. doi: 10.1080/17568919.2024.2385292. Epub 2024 Aug 19.
4
An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0003423. doi: 10.1128/cmr.00034-23. Epub 2024 May 1.
5
Post-translational modifications confer amphotericin B resistance in isolated from a neutropenic patient.
Front Immunol. 2023 Mar 1;14:1148681. doi: 10.3389/fimmu.2023.1148681. eCollection 2023.
6
Species Distribution and Antifungal Susceptibility Profile of Dermatophytes from a Tertiary Care Centre in North India.
J Lab Physicians. 2022 Jun 7;14(4):449-455. doi: 10.1055/s-0042-1748826. eCollection 2022 Dec.
7
State-of-the-Art Dermatophyte Infections: Epidemiology Aspects, Pathophysiology, and Resistance Mechanisms.
J Fungi (Basel). 2021 Aug 3;7(8):629. doi: 10.3390/jof7080629.
8
Familial Cases of Trichophyton benhamiae Infection Transmitted from a Guinea Pig in Iran.
Mycopathologia. 2021 Mar;186(1):119-125. doi: 10.1007/s11046-020-00513-1. Epub 2021 Jan 4.
9
Beyond the Superficial: Disseminated Infection in a Kidney Transplant Recipient.
Open Forum Infect Dis. 2020 Jul 5;7(7):ofaa281. doi: 10.1093/ofid/ofaa281. eCollection 2020 Jul.
10
Discovery of potential antifungal triazoles: design, synthesis, biological evaluation, and preliminary antifungal mechanism exploration.
Medchemcomm. 2017 Jun 15;8(8):1631-1639. doi: 10.1039/c7md00112f. eCollection 2017 Aug 1.
本文引用的文献
1
In vitro antifungal susceptibility of Trichophyton violaceum isolated from tinea capitis patients.
J Antimicrob Chemother. 2015 Apr;70(4):1072-5. doi: 10.1093/jac/dku503. Epub 2014 Dec 9.
2
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
Expert Rev Anti Infect Ther. 2015 Jan;13(1):9-27. doi: 10.1586/14787210.2015.990382.
3
In-vitro Activity of 10 Antifungal Agents against 320 Dermatophyte Strains Using Microdilution Method in Tehran.
Iran J Pharm Res. 2013 Summer;12(3):537-45.
4
In vitro activities of antifungal drugs against dermatophytes isolated in Tokat, Turkey.
Int J Dermatol. 2013 Dec;52(12):1557-60. doi: 10.1111/ijd.12100. Epub 2013 Oct 18.
5
Treatment of tinea capitis - griseofulvin versus fluconazole - a comparative study.
J Dtsch Dermatol Ges. 2013 Aug;11(8):737-41, 737-42. doi: 10.1111/ddg.12095. Epub 2013 Apr 10.
6
Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Antimicrob Agents Chemother. 2013 Apr;57(4):1610-6. doi: 10.1128/AAC.02056-12. Epub 2013 Jan 14.
7
Antifungal susceptibility patterns of yeasts and filamentous fungi isolated from nail infection.
J Eur Acad Dermatol Venereol. 2012 Dec;26(12):1479-85. doi: 10.1111/j.1468-3083.2011.04315.x. Epub 2011 Nov 3.
8
Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.
Mycopathologia. 2010 Nov;170(5):291-313. doi: 10.1007/s11046-010-9324-3. Epub 2010 Jun 5.
9
Update in antifungal therapy of dermatophytosis.
Mycopathologia. 2008 Nov-Dec;166(5-6):353-67. doi: 10.1007/s11046-008-9109-0. Epub 2008 May 14.
10
Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes.
Med Mycol. 2007 Nov;45(7):595-602. doi: 10.1080/13693780701549364.
Zotero 插件